VIDEO: Harrow CEO discusses Iheezo approval, fortified antibiotic

ByMark Baum

ByDavid W. Mullin

Fact checked byChristine Klimanskis, ELS

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — In this video from Eyecelerator@AAO, Harrow CEO Mark L. Baum discusses the recent FDA approval of Iheezo for ocular surface anesthesia as well as a new refrigeration-stable fortified antibiotic.

The combination of tobramycin and vancomycin will allow ophthalmologists to stock a fortified antibiotic in their offices for in-office treatment, he said.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Baum reports being CEO of Harrow.

Read more about

antibiotic

fda

ophthalmic business

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

• Facebook
• Twitter
• LinkedIn
• Email
• Print
• Comment